

Eric Florence

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5748181/publications.pdf>

Version: 2024-02-01

75
papers

1,959
citations

218592

26
h-index

265120

42
g-index

76
all docs

76
docs citations

76
times ranked

2860
citing authors

#	ARTICLE	IF	CITATIONS
1	Therapeutic Immunization with Dendritic Cells Loaded with Heat-Inactivated Autologous HIV-1 in Patients with Chronic HIV-1 Infection. <i>Journal of Infectious Diseases</i> , 2005, 191, 1680-1685.	1.9	147
2	HIV and Syphilis: When to Perform a Lumbar Puncture. <i>Sexually Transmitted Diseases</i> , 2007, 34, 141-144.	0.8	124
3	Sexual dysfunction associated with protease inhibitor containing highly active antiretroviral treatment. <i>Aids</i> , 2001, 15, 1019-1023.	1.0	98
4	Sexual dysfunction in HIV-positive men is multi-factorial: A study of prevalence and associated factors. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2007, 19, 955-965.	0.6	90
5	mRNA-based dendritic cell vaccination induces potent antiviral T-cell responses in HIV-1-infected patients. <i>Aids</i> , 2012, 26, F1-F12.	1.0	88
6	Antiretrovirals, Fractures, and Osteonecrosis in a Large International HIV Cohort. <i>Clinical Infectious Diseases</i> , 2017, 64, 1413-1421.	2.9	66
7	Hepatitis C virus infection in HIV-infected men who have sex with men: sustained rising incidence in Antwerp, Belgium, 2001-2009. <i>Eurosurveillance</i> , 2010, 15, .	3.9	65
8	Prevalence and factors associated with sexual dysfunction among HIV-positive women in Europe. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2004, 16, 550-557.	0.6	59
9	Transcriptome analysis of monocyte-HIV interactions. <i>Retrovirology</i> , 2010, 7, 53.	0.9	52
10	Decrease of vitamin D concentration in patients with HIV infection on a Non Nucleoside Reverse Transcriptase Inhibitor containing regimen. <i>AIDS Research and Therapy</i> , 2010, 7, 40.	0.7	50
11	Risk Factors for HCV Acquisition Among HIV-Positive MSM in Belgium. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2015, 68, 585-593.	0.9	50
12	Lipid Levels and Changes in Body Fat Distribution in Treatment-Naive, HIV-1-Infected Adults Treated With Rilpivirine or Efavirenz for 96 Weeks in the ECHO and THRIVE Trials. <i>Clinical Infectious Diseases</i> , 2014, 59, 425-434.	2.9	49
13	Rheumatological complications associated with the use of indinavir and other protease inhibitors. <i>Annals of the Rheumatic Diseases</i> , 2002, 61, 82-84.	0.5	48
14	Syphilis reinfections pose problems for syphilis diagnosis in Antwerp, Belgium - 1992 to 2012. <i>Eurosurveillance</i> , 2014, 19, 20958.	3.9	46
15	Immune and Viral Correlates of "Secondary Viral Control" after Treatment Interruption in Chronically HIV-1 Infected Patients. <i>PLoS ONE</i> , 2012, 7, e37792.	1.1	43
16	Swab2know: An HIV-Testing Strategy Using Oral Fluid Samples and Online Communication of Test Results for Men Who Have Sex With Men in Belgium. <i>Journal of Medical Internet Research</i> , 2015, 17, e213.	2.1	40
17	Treatment of acute hepatitis C genotypes 1 and 4 with 8 weeks of grazoprevir plus elbasvir (DAHHS2): an open-label, multicentre, single-arm, phase 3b trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2019, 4, 269-277.	3.7	39
18	Pulmonary effects of immediate versus deferred antiretroviral therapy in HIV-positive individuals: a nested substudy within the multicentre, international, randomised, controlled Strategic Timing of Antiretroviral Treatment (START) trial. <i>Lancet Respiratory Medicine</i> , 2016, 4, 980-989.	5.2	38

#	ARTICLE	IF	CITATIONS
19	HIV-1 V3 envelope deep sequencing for clinical plasma specimens failing in phenotypic tropism assays. <i>AIDS Research and Therapy</i> , 2010, 7, 4.	0.7	36
20	Increases in condomless chemsex associated with HIV acquisition in MSM but not heterosexuals attending a HIV testing center in Antwerp, Belgium. <i>AIDS Research and Therapy</i> , 2018, 15, 14.	0.7	35
21	Monocytes Contribute to Differential Immune Pressure on R5 versus X4 HIV through the Adipocytokine Visfatin/NAMPT. <i>PLoS ONE</i> , 2012, 7, e35074.	1.1	34
22	Rapid viral rebound after analytical treatment interruption in patients with very small HIV reservoir and minimal ongoing viral transcription. <i>Journal of the International AIDS Society</i> , 2020, 23, e25453.	1.2	33
23	The use of complementary and alternative medicine by persons with HIV infection in Europe. <i>International Journal of STD and AIDS</i> , 2003, 14, 672-674.	0.5	32
24	iHIVARNA phase IIa, a randomized, placebo-controlled, double-blinded trial to evaluate the safety and immunogenicity of iHIVARNA-01 in chronically HIV-infected patients under stable combined antiretroviral therapy. <i>Trials</i> , 2019, 20, 361.	0.7	31
25	A Standardized Algorithm for Determining the Underlying Cause of Death in HIV Infection as AIDS or non-AIDS Related: Results from the EuroSIDA Study. <i>HIV Clinical Trials</i> , 2011, 12, 109-117.	2.0	29
26	Efficient In Vitro Expansion of Human Immunodeficiency Virus (HIV)-Specific T-Cell Responses by <i>gag</i> mRNA-Electroporated Dendritic Cells from Treated and Untreated HIV Type 1-Infected Individuals. <i>Journal of Virology</i> , 2008, 82, 3561-3573.	1.5	26
27	Good continuum of HIV care in Belgium despite weaknesses in retention and linkage to care among migrants. <i>BMC Infectious Diseases</i> , 2015, 15, 496.	1.3	26
28	Using conventional HIV tests on oral fluid. <i>Journal of Virological Methods</i> , 2013, 194, 46-51.	1.0	25
29	Deteriorating renal function and clinical outcomes in HIV-positive persons. <i>Aids</i> , 2014, 28, 727-737.	1.0	25
30	Long-term Clinical Follow-up, without Antiretroviral Therapy, of Patients with Chronic HIV-1 Infection with Good Virological Response to Structured Treatment Interruption. <i>Clinical Infectious Diseases</i> , 2004, 39, 569-574.	2.9	23
31	A cross-sectional study of hepatitis C among people living with HIV in Cambodia: Prevalence, risk factors, and potential for targeted screening. <i>PLoS ONE</i> , 2017, 12, e0183530.	1.1	23
32	Comparison of phenotypic and genotypic tropism determination in triple-class-experienced HIV patients eligible for maraviroc treatment. <i>Journal of Antimicrobial Chemotherapy</i> , 2011, 66, 265-272.	1.3	22
33	Antiretroviral resistance at virological failure in the NEAT 001/ANRS 143 trial: raltegravir plus darunavir/ritonavir or tenofovir/emtricitabine plus darunavir/ritonavir as first-line ART. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 1056-1062.	1.3	22
34	The role of non-viral load surrogate markers in HIV-positive patient monitoring during antiviral treatment. <i>International Journal of STD and AIDS</i> , 2004, 15, 538-542.	0.5	21
35	Fever After a Stay in the Tropics: Clinical Spectrum and Outcome in HIV-Infected Travelers and Migrants. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2008, 48, 547-552.	0.9	21
36	Late presentation to HIV testing is overestimated when based on the consensus definition. <i>HIV Medicine</i> , 2016, 17, 231-234.	1.0	20

#	ARTICLE	IF	CITATIONS
37	Harm Reduction Practices and Needs in a Belgian Chemsex Context: Findings from a Qualitative Study. <i>International Journal of Environmental Research and Public Health</i> , 2020, 17, 9081.	1.2	20
38	High uptake of pre-exposure prophylaxis (PrEP) during early roll-out in Belgium: results from surveillance reports. <i>Sexual Health</i> , 2019, 16, 80.	0.4	19
39	Repeat syphilis has a different immune response compared with initial syphilis: an analysis of biomarker kinetics in two cohorts. <i>Sexually Transmitted Infections</i> , 2018, 94, 180-186.	0.8	18
40	Factors associated with the continuum of care of HIV-infected patients in Belgium. <i>Journal of the International AIDS Society</i> , 2014, 17, 19534.	1.2	17
41	Sexual Behavior and Sexually Transmitted Infections Among Swingers: Results From an Online Survey in Belgium. <i>Journal of Sex and Marital Therapy</i> , 2017, 43, 709-719.	1.0	16
42	Lipoplexes carrying mRNA encoding Gag protein modulate dendritic cells to stimulate HIV-specific immune responses. <i>Nanomedicine</i> , 2013, 8, 77-87.	1.7	14
43	Use of rapid HIV testing in a low threshold centre in Antwerp, Belgium, 2007-2012. <i>International Journal of STD and AIDS</i> , 2014, 25, 936-942.	0.5	13
44	PATIENTS WITH HIV INFECTION AND FEVER: A DIAGNOSTIC APPROACH. <i>Acta Clinica Belgica</i> , 2002, 57, 184-190.	0.5	12
45	Multiple Tuberculous Brain Abscesses in an HIV-Infected Patient Successfully Treated with HAART and Antituberculous Treatment. <i>Infection</i> , 2003, 31, 118-120.	2.3	11
46	Incidence and risk factors associated with lost to follow-up in a Belgian cohort of HIV-infected patients treated with highly active antiretroviral therapy. <i>International Journal of STD and AIDS</i> , 2010, 21, 765-769.	0.5	11
47	Control of viral replication after cessation of HAART. <i>AIDS Research and Therapy</i> , 2011, 8, 6.	0.7	10
48	INCIDENCE OF HCV AND SEXUALLY TRANSMITTED DISEASES AMONG HIV POSITIVE MSM IN ANTWERP, BELGIUM, 2001-2011. <i>Acta Clinica Belgica</i> , 2013, 68, 421-426.	0.5	10
49	CD4 results with a bias larger than hundred cells per microliter can have a significant impact on the clinical decision during treatment initiation of HIV patients. <i>Cytometry Part B - Clinical Cytometry</i> , 2017, 92, 476-484.	0.7	9
50	Validation of Clinical Scores for Risk Assessment. <i>Clinical Infectious Diseases</i> , 2012, 54, 1520-1521.	2.9	8
51	Voluntary outreach counselling and testing for HIV and STI among men who have sex with men in Antwerp. <i>Acta Clinica Belgica</i> , 2012, 67, 172-6.	0.5	8
52	PrEP user profiles, dynamics of PrEP use and follow-up: a cohort analysis at a Belgian HIV centre (2017-2020). <i>Journal of the International AIDS Society</i> , 2022, 25, .	1.2	7
53	Self-reported signs of lipodystrophy by persons living with HIV infection. <i>International Journal of STD and AIDS</i> , 2002, 13, 393-398.	0.5	6
54	Sustained HIV RNA suppression after switching from enfuvirtide to etravirine in the early access programme. <i>Journal of Antimicrobial Chemotherapy</i> , 2009, 64, 1341-1344.	1.3	6

#	ARTICLE	IF	CITATIONS
55	HIV RNA suppression rates after 24 weeks of treatment with etravirine, darunavir/ritonavir and raltegravir in the etravirine early access programme. <i>International Journal of STD and AIDS</i> , 2010, 21, 224-225.	0.5	6
56	Incidence rate, predictors and outcomes of interruption of HIV care: nationwide results from the Belgian HIV cohort. <i>HIV Medicine</i> , 2020, 21, 557-566.	1.0	6
57	The hepatitis C cascade of care in the Belgian HIV population: One step closer to elimination. <i>International Journal of Infectious Diseases</i> , 2021, 105, 217-223.	1.5	6
58	What is the significance of posttreatment control of HIV infection vis-à-vis functional cure?. <i>Aids</i> , 2014, 28, 603-605.	1.0	5
59	HIV testing for key populations in Europe: A decade of technological innovation and patient empowerment complement the role of health care professionals. <i>HIV Medicine</i> , 2018, 19, 71-76.	1.0	5
60	Isoniazid versus rifampicin and pyrazinamide for prevention of tuberculosis in HIV-1 infection. <i>Lancet</i> , The, 1998, 351, 1813.	6.3	4
61	Antiretroviral treatments used among adults with HIV infection in Europe. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2001, 13, 5-14.	0.6	4
62	PREVALENCE OF CHRONIC RENAL FAILURE STAGE 3 OR MORE IN HIV-INFECTED PATIENTS IN ANTWERP: AN OBSERVATIONAL STUDY. <i>Acta Clinica Belgica</i> , 2010, 65, 392-398.	0.5	4
63	Evaluation of the intercept oral specimen collection device with HIV assays versus paired serum/plasma specimens. <i>Journal of Virological Methods</i> , 2016, 234, 164-168.	1.0	4
64	Long-term effectiveness of recommended boosted protease inhibitor-based antiretroviral therapy in Europe. <i>HIV Medicine</i> , 2018, 19, 324-338.	1.0	4
65	Chlorhexidine mouthwash fails to eradicate oropharyngeal gonorrhoea in a clinical pilot trial (MoNg). <i>Sexually Transmitted Diseases</i> , 2021, Publish Ahead of Print, .	0.8	4
66	Safe and Effective Use of Combination Antiretroviral Treatment. <i>Acta Clinica Belgica</i> , 1999, 54, 55-60.	0.5	3
67	Vitros 5600 Syphilis TPA Assay. <i>Sexually Transmitted Diseases</i> , 2014, 41, 680-683.	0.8	3
68	Highly active antiretroviral treatment in countries with very limited resources: do we have cheaper alternatives?. <i>International Journal of STD and AIDS</i> , 2003, 14, 1-5.	0.5	2
69	Should We Screen HIV-Positive Migrants for Strongyloidiasis?. <i>Pathogens</i> , 2020, 9, 388.	1.2	2
70	Self-Control as Conceptual Framework to Understand and Support People Who Use Drugs During Sex. <i>Frontiers in Public Health</i> , 0, 10, .	1.3	2
71	Five-year immunological outcome of highly active antiretroviral treatment in a clinical setting: results from a single HIV treatment centre. <i>International Journal of STD and AIDS</i> , 2004, 15, 523-528.	0.5	1
72	Prevalence of chronic renal failure stage 3 or more in HIV-infected patients in Antwerp: an observational study. <i>Journal of the International AIDS Society</i> , 2010, 13, P89.	1.2	1

#	ARTICLE	IF	CITATIONS
73	HIV and sexual dysfunction. International Journal of STD and AIDS, 2003, 14, 69-69.	0.5	1
74	Superimposing incident sexually transmitted infections on HIV phylogram to investigate possible misclassification of men who have sex with men as heterosexuals in a cohort in Antwerp, Belgium. International Journal of STD and AIDS, 2019, 30, 486-495.	0.5	0
75	Impact of PrEP on a STI clinic in a Belgian context: a provider's perspective. Acta Clinica Belgica, 2020, 76, 1-5.	0.5	0